Akebia Therapeutics
AKBA
61 hedge funds and large institutions have $88.2M invested in Akebia Therapeutics in 2015 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
64% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 14
7% more funds holding
Funds holding: 57 → 61 (+4)
7% less capital invested
Capital invested by funds: $94.4M → $88.2M (-$6.21M)
22% less call options, than puts
Call options by funds: $348K | Put options by funds: $445K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$2.74M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$921K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$602K |
| 4 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
+$532K |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$457K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$2.67M |
| 2 |
Millennium Management
New York
|
-$1.01M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$1.01M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$961K |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$890K |
AKBA Hedge Fund Activity: Q1 2015 in Review
61 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2015, worth a combined $88.2M — down 6.6% from $94.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new AKBA positions and 6 closed out — a net gain of 4 holders — while 23 added to existing stakes and 14 trimmed.
The largest buyer was Emerald Mutual Fund Advisers Trust, opening a new position worth an estimated $2.74M. The largest seller was HealthCor Management, cutting an estimated $2.67M.
- 61 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2015, up from 57 in Q4 2014.
- Funds reported $88.2M of Akebia Therapeutics stock for Q1 2015, down 6.6% quarter-over-quarter.
- 10 funds opened new Akebia Therapeutics positions in Q1 2015 and 6 closed out, a net change of +4 holders.
- The largest Akebia Therapeutics buyer in Q1 2015 was Emerald Mutual Fund Advisers Trust, an estimated $2.74M added.
- The largest Akebia Therapeutics seller in Q1 2015 was HealthCor Management, an estimated $2.67M sold.
Based on aggregated 13F filings for Q1 2015.